Compare Amgen, Inc. (AMGN) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs J B Hunt Transport Services Inc — how do they compare? Amgen, Inc. trades at $358.74 (market cap $196.12B), while J B Hunt Transport Services Inc trades at $284.19 (market cap $26.40B). The key difference: Amgen, Inc. is far larger — about 7.4× J B Hunt Transport Services Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | JBHT | |
|---|---|---|
Market Cap | $196.12B | $26.40B |
Sector | Health | Industrials |
52-Week High | $388.16 | $290.07 |
52-Week Low | $271.18 | $130.65 |
Enterprise Value | $241.41B | $27.70B |
Dividend Yield | 2.77% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JBHT trades at $279.96, down 0.94% today, with a bullish technical outlook supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue has stabilized around $12B annually, while profitability metrics show a net margin of 5.13% and ROE of 16.68%. Analyst sentiment remains positive with 57.78% buy ratings.
The stock presents a mixed valuation with elevated P/E of 43.47 but reasonable EV/EBITDA of 17.18. Near-term catalysts include Q2 earnings release on July 15, 2026. Key risks include freight market volatility and competitive pressures. The consensus price target of $273.93 suggests limited upside from current levels despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
